Mostrar el registro sencillo del ítem
| dc.contributor.author | Cortes-Hernández, Josefina | |
| dc.contributor.author | Marras-Fernández-Cid, Carlos | |
| dc.contributor.author | Andreu-Sánchez, José-Luis | |
| dc.contributor.author | Calvo-Alen, Jaime | |
| dc.contributor.author | García-Aparicio, Ángel-M | |
| dc.contributor.author | Díez-Álvarez, Elvira | |
| dc.contributor.author | Hidalgo-Bermejo, Francisco-Javier | |
| dc.contributor.author | Coronell, Carlos | |
| dc.contributor.author | Perna, Alessandra | |
| dc.contributor.author | Ordi-Ros, Josep | |
| dc.date.accessioned | 2025-12-03T11:13:22Z | |
| dc.date.available | 2025-12-03T11:13:22Z | |
| dc.date.issued | 2023-06 | |
| dc.identifier.citation | Cortés-Hernández J, Marras Fernández-Cid C, Andreu Sánchez JL, Calvo Alén J, García-Aparicio AM, Díez Álvarez E, et al. Reduction of disease activity, corticosteroids use, and healthcare resource utilisation in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: OBSErve Spain multicentre study. Reumatología Clínica. junio de 2023;19(6):312-8. | |
| dc.identifier.issn | 1699-258X | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/22958 | |
| dc.description.abstract | INTRODUCTION AND OBJECTIVES: This OBSErve Spain study, a part of the international OBSErve programme, evaluated belimumab real-world use and effectiveness following 6 months of treatment in patients with active systemic lupus erythematosus (SLE) in clinical practice in Spain. MATERIALS AND METHODS: In this retrospective, observational study (GSK Study 200883), eligible patients with SLE receiving intravenous belimumab (10mg/kg) had their disease activity (physician assessed), SELENA-SLEDAI scores, corticosteroid use, and healthcare resource utilisation (HCRU), assessed after 6 months of treatment versus index (belimumab initiation) or 6 months pre-index. RESULTS: Overall, 64 patients initiated belimumab, mainly due to ineffectiveness of previous treatments (78.1%) and to reduce corticosteroid use (57.8%). Following 6 months of treatment, 73.4% of patients achieved ?20% overall clinical improvement, while only 3.1% of patients worsened. Mean (standard deviation, SD) SELENA-SLEDAI score decreased from 10.1 (6.2) at index to 4.5 (3.7) 6 months post-index. HCRU decreased from 6 months pre-index to 6 months post-index, with fewer hospitalisations (10.9% vs 4.7% patients) and ER visits (23.4% vs 9.4% patients). Mean (SD) corticosteroid dose decreased from 14.5 (12.5)mg/day at index to 6.4 (5.1)mg/day 6 months post-index. CONCLUSIONS: Patients with SLE receiving belimumab for 6 months in real-world clinical practice in Spain experienced clinical improvements and a reduction in HCRU and corticosteroid dose. | |
| dc.language.iso | eng | |
| dc.publisher | ELSEVIER ESPANA SLU | |
| dc.rights | Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | * |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Immunosuppressive Agents/adverse effects | |
| dc.subject.mesh | Retrospective Studies | |
| dc.subject.mesh | Spain | |
| dc.subject.mesh | Treatment Outcome | |
| dc.subject.mesh | Adrenal Cortex Hormones/therapeutic use | |
| dc.subject.mesh | Lupus Erythematosus, Systemic/drug therapy | |
| dc.subject.mesh | Patient Acceptance of Health Care | |
| dc.title | Reduction of disease activity, corticosteroids use, and healthcare resource utilisation in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: OBSErve Spain multicentre study | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 37286267 | |
| dc.relation.publisherversion | https://linkinghub.elsevier.com/retrieve/pii/S1699258X22001589 | |
| dc.identifier.doi | 10.1016/j.reuma.2022.08.001 | |
| dc.journal.title | Reumatologia Clinica | |
| dc.identifier.essn | 1885-1398 |